NeoPharm CO., LTD. (KOSDAQ:092730)
South Korea · Delayed Price · Currency is KRW 17,170
-10 (-0.06%)
Apr 10, 2026, 3:30 PM KST
NeoPharm CO., LTD. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 132,184 | 119,014 | 97,105 | 85,033 | 87,931 |
Other Revenue | - | - | - | -0 | - |
| 132,184 | 119,014 | 97,105 | 85,033 | 87,931 | |
Revenue Growth (YoY) | 11.07% | 22.56% | 14.20% | -3.29% | 7.72% |
Cost of Revenue | 45,786 | 44,987 | 31,720 | 26,653 | 25,544 |
Gross Profit | 86,398 | 74,027 | 65,385 | 58,380 | 62,386 |
Selling, General & Admin | 52,602 | 44,259 | 36,276 | 32,984 | 36,022 |
Research & Development | 3,335 | 3,407 | 2,647 | 2,854 | 2,935 |
Amortization of Goodwill & Intangibles | 258.4 | 491.92 | 414.51 | 416.67 | 420.2 |
Operating Expenses | 57,624 | 49,374 | 40,078 | 36,941 | 39,955 |
Operating Income | 28,775 | 24,653 | 25,307 | 21,439 | 22,431 |
Interest Expense | -39.42 | -40.78 | -21.32 | -8.84 | -38.46 |
Interest & Investment Income | 3,780 | 4,155 | 4,588 | 2,077 | 1,177 |
Currency Exchange Gain (Loss) | -308.18 | 2,006 | -117.74 | 205.38 | 662.9 |
Other Non Operating Income (Expenses) | 27.4 | -795.4 | -362.95 | -376.73 | -430.38 |
EBT Excluding Unusual Items | 32,234 | 29,978 | 29,393 | 23,335 | 23,801 |
Gain (Loss) on Sale of Investments | -31.81 | 251.15 | -2.76 | - | 48.48 |
Gain (Loss) on Sale of Assets | 59.1 | -17.17 | -3.7 | -6.05 | -3.23 |
Asset Writedown | -0.58 | -3.3 | -13.47 | -6.23 | -11.07 |
Pretax Income | 32,261 | 30,209 | 29,373 | 23,323 | 23,836 |
Income Tax Expense | 4,438 | 7,144 | 6,160 | 6,296 | 6,122 |
Net Income | 27,823 | 23,065 | 23,213 | 17,027 | 17,713 |
Net Income to Common | 27,823 | 23,065 | 23,213 | 17,027 | 17,713 |
Net Income Growth | 20.63% | -0.64% | 36.33% | -3.87% | -2.30% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 |
Shares Change (YoY) | - | - | - | - | -0.95% |
EPS (Basic) | 1778.81 | 1474.61 | 1484.07 | 1088.60 | 1132.47 |
EPS (Diluted) | 1778.81 | 1474.61 | 1484.00 | 1088.50 | 1132.47 |
EPS Growth | 20.63% | -0.63% | 36.33% | -3.88% | -1.35% |
Free Cash Flow | 27,225 | 15,832 | 3,411 | 17,707 | 21,361 |
Free Cash Flow Per Share | 1740.59 | 1012.16 | 218.06 | 1132.04 | 1365.69 |
Dividend Per Share | 750.000 | 600.000 | 375.000 | 350.000 | 350.000 |
Dividend Growth | 25.00% | 60.00% | 7.14% | - | 7.69% |
Gross Margin | 65.36% | 62.20% | 67.33% | 68.66% | 70.95% |
Operating Margin | 21.77% | 20.71% | 26.06% | 25.21% | 25.51% |
Profit Margin | 21.05% | 19.38% | 23.91% | 20.02% | 20.14% |
Free Cash Flow Margin | 20.60% | 13.30% | 3.51% | 20.82% | 24.29% |
EBITDA | 31,930 | 27,803 | 26,980 | 23,055 | 23,931 |
EBITDA Margin | 24.16% | 23.36% | 27.79% | 27.11% | 27.22% |
D&A For EBITDA | 3,156 | 3,150 | 1,673 | 1,616 | 1,500 |
EBIT | 28,775 | 24,653 | 25,307 | 21,439 | 22,431 |
EBIT Margin | 21.77% | 20.71% | 26.06% | 25.21% | 25.51% |
Effective Tax Rate | 13.76% | 23.65% | 20.97% | 27.00% | 25.69% |
Advertising Expenses | 16,505 | 13,563 | 12,408 | 11,533 | 14,695 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.